Clinical questions formulated and prioritized
| Questions determined by the panel |
| 1. Should older adults with newly diagnosed AML who are candidates for antileukemic therapy receive antileukemic therapy instead of best supportive care only? |
| 2. Should older adults with newly diagnosed AML considered candidates for antileukemic therapy receive intensive antileukemic therapy vs less-intensive antileukemic therapy? |
| 3. Should older adults with newly diagnosed AML who achieve remission after at least 1 cycle of intensive antileukemic therapy receive postremission therapy vs no additional therapy? |
| 4. Should older adults with AML considered appropriate for antileukemic therapy but not for intensive antileukemic therapy receive gemtuzumab ozogamicin, low-dose cytarabine, azacitidine, 5-d decitabine, or 10-d decitabine as monotherapy or in combination? |
| 5. Should older adults with AML who received less-intensive antileukemic therapy and who achieved a response continue therapy indefinitely until progression/toxicity or be given therapy for a finite number of cycles? |
| 6. Should older adults with AML who are no longer receiving antileukemic therapy (including those receiving end-of-life or hospice care) receive RBC transfusions, platelet transfusions, or both, vs no transfusions? |
| Questions determined by the panel |
| 1. Should older adults with newly diagnosed AML who are candidates for antileukemic therapy receive antileukemic therapy instead of best supportive care only? |
| 2. Should older adults with newly diagnosed AML considered candidates for antileukemic therapy receive intensive antileukemic therapy vs less-intensive antileukemic therapy? |
| 3. Should older adults with newly diagnosed AML who achieve remission after at least 1 cycle of intensive antileukemic therapy receive postremission therapy vs no additional therapy? |
| 4. Should older adults with AML considered appropriate for antileukemic therapy but not for intensive antileukemic therapy receive gemtuzumab ozogamicin, low-dose cytarabine, azacitidine, 5-d decitabine, or 10-d decitabine as monotherapy or in combination? |
| 5. Should older adults with AML who received less-intensive antileukemic therapy and who achieved a response continue therapy indefinitely until progression/toxicity or be given therapy for a finite number of cycles? |
| 6. Should older adults with AML who are no longer receiving antileukemic therapy (including those receiving end-of-life or hospice care) receive RBC transfusions, platelet transfusions, or both, vs no transfusions? |